Member Info for Indie07

The SP should have hit 2p plus then! DYOR

Work out the Mcap and where it should be
All to play for

This should be at minimum of 2p now
Just re rating after yesterday’s RNS
DYOR

Good Thursday tomorrow, watch this accelerate

Yesterday!

?

.

NICE

The company had previously reported positive data from the Clinical Study of Nasal Administration with Foralumab in COVID-19 patients in Brazil. Nasally administered Foralumab at 100 mg/day for consecutive 10 days treatment was found to be well-tolerated, and there were no apparent severe adverse events. The clinical data suggested that the treatment provided significant reduction of lung inflammation.



About Foralumab

Foralumab (formerly NI-0401), the only entirely human anti-CD3 mAb, shows reduced release of cytokines after IV administration in patients with Crohn's disease with decreases in the classic side effects of cytokine release syndrome and improves the overall safety profile of Foralumab. In a humanized mouse model (NOD/SCID IL2?c-/-), it was shown that whilst targeting the T cell receptor, orally administered Foralumab modulates immune responses of the T cells, enhances regulatory T-cells (Tregs) and thus provides therapeutic benefit in treating inflammatory and autoimmune diseases without the occurrence of potential adverse events usually associated with parenteral mAb therapy (Ogura M. et al., 2017). Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.

.

?

News?

Never know when they will drop
Catch all unaware

Thank you deramppppers
I’ve topped up nicely

...

Looks like all the right moves in the right direction... exciting times

R N S
@Trevor Brown, CEO of Braveheart, commented "These results have exceeded even our ambitious expectations and are a credit to Professor Smythe and his tireless team."

Don’t blame the derampers, they are desperate to get in...same old story

IMHO, I will hang in for longer get this time,
DYOR

BRH has leapfrogged and then some

DYOR